Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.03, with a volume of 839,780 shares traded.
Mateon Therapeutics Stock Performance
The company’s 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Read More
- Five stocks we like better than Mateon Therapeutics
- What is Put Option Volume?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- ETF Screener: Uses and Step-by-Step Guide
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Insider Trades May Not Tell You What You Think
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
